A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity

Uday S. Ganapathy, a Rubén González del Rio, b Mónica Cacho-Izquierdo, b Fátima Ortega, b Joël Lelièvre, b David Barros-Aguirre, b Marissa Lindman, a,* Véronique Dartois, a,c Martin Gengenbacher, a,c Thomas Dick a,c,d #

a Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA
b Global Health R&D, GlaxoSmithKline, Tres Cantos, Spain
c Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA
d Department of Microbiology and Immunology, Georgetown University, Washington, DC, USA

Running Title: Benzoxaborole with Broad Anti-Mycobacterial Activity

Keywords: Benzoxaborole, EC/11770, Mycobacterium abscessus, NTM, non-tuberculous mycobacteria, leucyl-tRNA synthetase

#Address correspondence to Thomas Dick, thomas.dick@hmh-cdi.org

*Present address: Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, USA
Global infections by non-tuberculous mycobacteria (NTM) are steadily rising. New drugs are needed to treat NTM infections, but the NTM drug pipeline remains poorly populated and focused on repurposing or reformulating approved antibiotics. We sought to accelerate de novo NTM drug discovery by testing advanced compounds with established activity against *Mycobacterium tuberculosis*. 3-aminomethyl 4-halogen benzoxaboroles, a novel class of leucyl-tRNA synthetase inhibitors, were recently discovered as active against *M. tuberculosis*. Here, we report that the benzoxaborole EC/11770 is not only a potent anti-tubercular agent but is active against the *M. abscessus* and *M. avium* complexes. Focusing on *M. abscessus*, which causes the most difficult-to-cure NTM disease, we show that EC/11770 retained potency against drug-tolerant biofilms *in vitro* and was effective in a mouse lung infection model. Resistant mutant selection experiments showed a low frequency of resistance and confirmed leucyl-tRNA synthetase as the target. This work establishes the benzoxaborole EC/11770 as a novel preclinical candidate for the treatment of NTM lung disease and tuberculosis and validates leucyl-tRNA synthetase as an attractive target for the development of broad-spectrum anti-mycobacterials.

**INTRODUCTION**

Non-tuberculous mycobacteria (NTM) are a group of opportunistic pathogens belonging to the same genus as *Mycobacterium tuberculosis*, the causative agent of tuberculosis (TB) (1). Like *M. tuberculosis*, NTM pathogenesis often manifests as lung disease, requiring lengthy treatment with multi-drug regimens. But while global TB cases have decreased in recent years, global
NTM cases have steadily risen (2), highlighting the unique treatment challenges that these infections pose.

NTM lung infections are primarily caused by members of the *M. abscessus* and *M. avium* complexes. Despite similarities to *M. tuberculosis*, these NTM species display notable differences in their pathogenesis due to their expression of unique surface lipids, adaptation to both host and environmental niches, and acquisition of novel virulence strategies (3). While pulmonary infections are most common, *M. abscessus* and *M. avium* pathogenesis can also manifest as severe disseminated disease in immunocompromised individuals (4). *M. abscessus* and *M. avium* also exhibit intrinsic drug resistance to many classes of antibiotics typically administered to treat TB (5-7). The situation is most severe for *M. abscessus* infections, which are resistant to all first-line TB drugs and for which no curative treatment is available. As a result, the drug regimens for NTM lung disease are markedly different from the standard four-drug TB regimen and vary by species (8-10). For infections caused by *M. avium* complex, combination therapy with a macrolide (clarithromycin or azithromycin) and two TB drugs (ethambutol and rifampicin) is recommended (10). Treatment of *M. abscessus* lung disease, however, involves combination of a macrolide with parenterally administered antibiotics, typically an aminoglycoside and either imipenem, cefoxitin or tigecycline as a third drug. While the potency of macrolides against *M. abscessus* can be limited by *erm41*-mediated inducible drug resistance (11), these compounds can still provide beneficial immunomodulatory effects such as reducing airway secretion to promote mucociliary clearance (12, 13). The fact that *M. abscessus* chemotherapy requires intravenous drug administration is another complicating factor not encountered in *M. avium* treatment, where all drugs can be administered orally. In both cases,
treatment typically lasts 18-24 months, produces severe drug side-effects and drives acquired drug resistance. Worst of all, treatment outcomes for NTM lung disease remain poor with cure rates averaging 60% for *M. avium* infections and 50% for *M. abscessus* infections (14, 15).

Given the poor performance of current NTM treatment regimens, new drugs are urgently needed to combat the rise in NTM infections (16). Ideally, new NTM drugs would have novel targets and mechanisms of action that can overcome both intrinsic and acquired drug resistance (17). The introduction of new drugs to NTM drug regimens could shorten treatment times, reducing adverse side-effects and opportunity for acquired drug resistance. Unfortunately, the current NTM drug pipeline is sparsely populated and mostly focused on repurposing or reformulation of approved antibiotics (17, 18). *De novo* drug discovery campaigns remain largely absent due to their higher attrition rates compared to repurposing strategies, making them slower and costlier endeavors.

We have recently devised a two-part strategy to accelerate *de novo* NTM drug discovery. First, we selectively screen TB actives for anti-NTM activity. Since *M. avium* and *M. abscessus* are genetically related to *M. tuberculosis*, the likelihood that TB actives have homologous targets in these species will be greater. Indeed, screening TB actives yields a higher hit rate than screening a random compound collection (19). Second, we prioritize the screening of advanced compounds. With established pharmacokinetics (PK) and tolerability, advanced compounds circumvent several critical hurdles in *de novo* drug discovery, allowing them to move rapidly from *in vitro* NTM actives to lead compounds with demonstrated *in vivo* efficacy (20). With this strategy in mind, we sought to identify drug classes with novel bacterial targets and
demonstrated activity against *M. tuberculosis*. The screening of advanced compounds from these drug classes would offer a shorter path to the discovery of new NTM drugs.

Amino-acyl tRNA synthetases (aaRSs) are enzymes that correctly attach each amino acid to its cognate tRNA molecule, enabling proper translation of the genetic code (21). Given this critical role in protein biosynthesis, aaRSs represent potential antibiotic targets. While the organization of aaRS catalytic domains into two structurally distinct classes is conserved across all domains of life, there remain substantial structural differences between the aaRS catalytic domains of prokaryotes and eukaryotes (22). Therefore, a pathogen-specific aaRS inhibitor could be developed that does not target the human host enzyme. Mupirocin, the first clinically approved aaRS inhibitor, inhibits the aminoacylation activity of isoleucyl-tRNA synthetase (IleRS) by competing with isoleucine for binding to the enzyme’s catalytic domain (23, 24). While mupirocin is most active against Gram-positive bacteria, it is inactive against mycobacteria (25). Furthermore, mupirocin has poor bioavailability, restricting its use to topical treatment of skin infections and rendering this class of aaRS inhibitor unsuitable for the treatment of mycobacterial lung infections.

Benzoxaboroles are a class of boron-heterocyclic compounds that were first described as having potent anti-fungal activity (26). *Saccharomyces cerevisiae* mutants resistant to benzoxaborole AN2690 had mutations in the gene encoding leucyl-tRNA synthetase (LeuRS), suggesting that benzoxaboroles are aaRS inhibitors (27). In addition to a catalytic domain, several aaRSs contain an editing domain that can hydrolyze incorrectly charged tRNAs, providing a critical proofreading function that ensures fidelity of the genetic code (28). Intriguingly, all of the LeuRS
mutations identified in the *S. cerevisiae* AN2690-resistant mutants mapped to the editing domain, indicating that benzoxaboroles and mupirocin have different mechanisms of action (27).

Crystallographic studies revealed that the oxaborole ring of AN2690 enables the formation of an AN2690-tRNA\(^{\text{Leu}}\) adduct that binds to the LeuRS editing domain. This oxaborole tRNA trapping (OBORT) mechanism efficiently inhibits protein synthesis by blocking leucyl-tRNA\(^{\text{Leu}}\) synthesis (27).

Following a screening campaign by GlaxoSmithKline, 3-aminomethyl 4-halogen benzoxaboroles were identified as active against *M. tuberculosis* (29). Benzoxaborole-resistant mutants also carried mutations in the LeuRS editing domain, validating LeuRS as a TB drug target (29).

Additional structure–activity relationship studies around the benzoxaborole scaffold led to the discovery of GSK3036656 (GSK656, Fig. 1), which had attractive *in vivo* PK and demonstrated efficacy in a mouse model of TB infection (30). In 2019, a first-time-in-human study demonstrated the safety and tolerability of GSK656 (31), furthering the development of this benzoxaborole as a promising new TB drug. Given the anti-tubercular activity of GSK656, we asked whether this compound and its close analog EC/11770 (Fig. 1) are active against NTM.

Surprisingly, we found that GSK656 showed a restricted NTM spectrum, whereas EC/11770 displayed broad anti-NTM activity. Through detailed *in vitro* and *in vivo* profiling, we have established EC/11770 as a novel preclinical candidate for the treatment of NTM lung disease.

**RESULTS**

EC/11770 is active against *M. abscessus* and *M. avium* *in vitro*.  
GSK656 and its close analog EC/11770 (Fig. 1) have potent activity against M. tuberculosis (MIC values of 0.08 µM and 0.56 µM, respectively; Table 1) (30). Therefore, we asked whether these compounds have activity against M. abscessus and M. avium in Middlebrook 7H9 medium. For these experiments, we used two recent clinical isolates of these NTM species: M. abscessus Bamboo (subsp. abscessus) (32) and M. avium 11 (subsp. hominissuis) (33). While GSK656 was active against M. abscessus Bamboo, this compound had no activity against M. avium 11 (Table 1). Surprisingly, EC/11770 was active against both M. abscessus Bamboo and M. avium 11 (Table 1). Since composition of the medium and the presence of detergents can affect potency (34, 35), we measured the MIC of EC/11770 in cation-adjusted Mueller-Hinton (CAMH) broth, which is the clinical standard for antibiotic susceptibility testing, has a different carbon source composition from 7H9, and lacks detergent (36). EC/11770 retained its potency against M. abscessus Bamboo in CAMH (Table 1). Thus, the benzoxaborole EC/11770 demonstrated dual activity against M. abscessus and M. avium screening strains, and this activity was culture medium independent.

**EC/11770 has broad spectrum anti-NTM activity.**

As EC/11770 was active against M. abscessus Bamboo (Table 1), we asked whether EC/11770 is active against all three subspecies of the M. abscessus complex (subsp. abscessus, subsp. massiliense, and subsp. bolletii), which are known to exhibit differences in antibiotic susceptibility (8, 37). EC/11770 showed comparable potency against culture collection reference strains for all three M. abscessus subspecies (Table 2). Furthermore, EC/11770 retained its activity against a panel of clinical isolates of M. abscessus that cover the M. abscessus complex (Table 2) (38). EC/11770 was also active against M. abscessus subsp. abscessus K21, a clinical
isolate used in our *M. abscessus* mouse infection model (Table 2) (39). The *M. avium* complex consists of 12 distinct species of which three (*M. avium*, *M. intracellulare*, and *M. chimaera*) are the most common causative agents of NTM lung disease (10, 40). Given EC/11770’s activity against *M. avium* 11 (Table 1), we asked whether this compound has activity against other members of the *M. avium* complex. Indeed, EC/11770 inhibited the growth of culture collection reference strains of *M. intracellulare* and *M. chimaera* (Table 2). Thus, EC/11770 displayed broad-spectrum anti-mycobacterial activity that targets *M. tuberculosis*, and the *M. abscessus* and *M. avium* complexes. As *M. abscessus* NTM disease is the most difficult to cure, we focused subsequent analyses of EC/11770 on this mycobacterial species.

**EC/11770 is bacteriostatic against *M. abscessus* in vitro.**

Benzoaboroles lack bactericidal activity against *M. tuberculosis* (29), making them bacteriostatic compounds. We asked whether EC/11770 is also bacteriostatic against *M. abscessus* by determining the MIC/MBC of this compound against planktonic bacteria growing in culture tubes (as opposed to the wells of 96-well plates) (41). Under these conditions, clarithromycin inhibited the growth of *M. abscessus* Bamboo (MIC = 0.28 µM) but had no bactericidal activity (minimum bactericidal concentration [MBC] > 100 µM) (Table 3), consistent with the bacteriostatic profile of macrolides against this bacterium (41). Similarly, EC/11770 had growth inhibitory activity against *M. abscessus* Bamboo (MIC = 3 µM) but was not bactericidal (MBC > 100 µM) (Table 3). Consistent with *M. tuberculosis* potency data (29), these results demonstrated that benzoaboroles are also bacteriostatic against NTM like *M. abscessus*. 
EC/11770 inhibits the growth of *M. abscessus* biofilms.

*M. abscessus* forms biofilms that are tolerant to several classes of antibiotics active against planktonic cultures of the pathogen (41-43). We therefore assessed the potency of EC/11770 in an *in vitro* *M. abscessus* biofilm growth assay (41). Similar to clarithromycin, EC/11770 inhibited *M. abscessus* biofilm growth but did not have bactericidal activity against *M. abscessus* in established biofilms (Table 3). These results are consistent with the bacteriostatic activity of both compounds against *M. abscessus* in culture tubes (Table 3). But while the MIC of clarithromycin increased 5-6 fold against *M. abscessus* biofilms, EC/11770 was as active against the biofilm and planktonic forms of the bacterium (Table 3). Thus, EC/11770 retained the potent growth inhibitory activity it displays in broth culture against *M. abscessus* biofilms.

**EC/11770 targets *M. abscessus* leucyl-tRNA synthetase LeuRS.**

Benzoxaboroles were first discovered as inhibitors of LeuRS in fungi (27). In both *M. tuberculosis* and *M. smegmatis*, benzoxaborole-resistant mutants harbored point mutations in the gene encoding LeuRS (29), which has a homolog in *M. abscessus* (*leuS*, MAB_4923c). To determine whether LeuRS is the target of EC/11770 in *M. abscessus*, we selected for EC/11770-resistant mutants of *M. abscessus* Bamboo (Table 4). Based on two independent selections, we calculated a frequency of resistance to EC/11770 of $3.9 \times 10^{-8}$/CFU which was significantly lower than that reported for benzoxaboroles in *M. tuberculosis* ($3.9 - 4.6 \times 10^{-6}$/CFU) (29). MIC profiling of five EC/11770-resistant mutants (RM1-5) showed high level resistance to EC/11770 but no change in susceptibility to clarithromycin (Table 4). The EC/11770 MIC for two of the mutants (RM3 and RM5) was between 60 and 75 µM, while the remaining mutants’ EC/11770 MIC was greater than 100 µM. Sequencing of *leuS* revealed that all five resistant strains carried a
single missense mutation in the LeuRS editing domain (residues V292 to K502), consistent with the OBORT mechanism of benzoxaboroles (Table 4, Fig. S1) (27). RM1 carried a A428P substitution, a residue that was mutated in previously reported *M. smegmatis* benzoxaborole-resistant mutants (A to T) (29). RM4 had a T327R mutation, which maps to a threonine residue that was mutated in an *S. cerevisiae* benzoxaborole-resistant mutant (T319I) (27). The two other LeuRS missense mutations in the editing domain (K502E and V417M) were novel (27, 29). One of these novel missense mutations, V417M, was isolated twice from independent selection experiments (RM3 and RM5, Table 4). We conclude that EC/11770’s anti-NTM activity is mediated by targeting the editing domain of LeuRS as previously described for other benzoxaboroles (27, 29).

**Pharmacokinetic properties of EC/11770.**

EC/11770 exhibited attractive physicochemical properties leading to high solubility and permeability (Table 5). The low intrinsic clearance observed in mouse and human microsomes (<0.5 ml/min/g tissue) predicted the very low *in vivo* clearance obtained in mice: intravenous administration of 1 mg/kg saline solution resulted in an *in vivo* clearance rate of 5 ml/min/kg, corresponding to approximately 5% of the liver blood flow in mice (90-126 ml/min/kg) (Table 5). This low *in vivo* clearance, combined with a moderate volume of distribution, translated into a high average half-life in mice of 5.3 hours (Fig. 2, Table 5). After oral administration of EC/11770 at 1 mg/kg or 10 mg/kg, a high oral bioavailability was obtained for both doses (100%) (Fig. 2, Table 5). These results are consistent with EC/11770’s good solubility, permeability and low *in vivo* clearance (Table 5). EC/11770’s low *in vivo* clearance also minimizes the oral first-pass effect (Table 5). Additionally, the compound presented a reasonably...
linear pharmacokinetic behavior between the two oral doses: drug exposure increased proportionally with the increase in dosage, as reflected in the similar dose-normalized exposures obtained for both dosages (Table 5, dose-normalized area under the concentration-time curve, or DNAUC). Using these PK results and the potency data, we determined that 10 mg/kg would achieve 100% time above MIC in *M. abscessus* planktonic cultures, and approximately 60% time above *M. abscessus* biofilm MIC (Fig. 2) (EC/11770 is known to be tolerated at doses up to 100 mg/kg in TB efficacy studies).

**EC/11770 is active against *M. abscessus* in vivo.**

To determine whether EC/11770 has anti-NTM activity *in vivo*, we examined whether this compound was active against *M. abscessus* in a murine infection model (39). NOD SCID mice were infected intranasally with *M. abscessus* subsp. *abscessus* K21. On Day 1 post-infection, the lung bacterial burden reached $6.5 \times 10^6$ CFU (Fig. 3A). Starting on Day 1, 10 mg/kg EC/11770, 250 mg/kg clarithromycin or drug free vehicle was administered orally to mice once daily for ten days. In mice given the drug free vehicle control, the lung bacterial burden remained unchanged after ten days (Fig. 3A, Day 11). Treatment with EC/11770 at 10 mg/kg achieved a statistically significant 1.5-log reduction in lung CFU, superior though not statistically significantly so, to clarithromycin at 250 mg/kg (Fig. 3A). We observed a similar pattern of CFU reduction in the spleen (Fig. 3B). Thus, EC/11770 demonstrated efficacy against *M. abscessus* in a preclinical mouse infection model.

**DISCUSSION**
To fast-track de novo NTM drug discovery, we sought to test advanced TB active compounds for anti-NTM activity. We therefore tested the benzoxaborole GSK656 and its close analog EC/11770, which both display submicromolar growth inhibitory activity against *M. tuberculosis*. Interestingly, we found that GSK656 was only active against *M. abscessus* and inactive against *M. avium*, whereas EC/11770 showed *in vitro* potency against a collection of *M. abscessus* and *M. avium* strains covering a range of subspecies. Critically, EC/11770 demonstrated attractive efficacy in our *M. abscessus* mouse model, paving the way for this compound to be pursued as a preclinical candidate for NTM. Thus, EC/11770 provides proof-of-principle for de novo NTM drug discovery starting from TB actives. With EC/11770’s anti-NTM activity, we also established LeuRS as an NTM drug target. This allows other benzoxaboroles to be considered as potential NTM drug candidates, further enabling development of antibiotics for NTM infections.

In contrast to EC/11770’s broad anti-NTM activity, it was somewhat surprising that the structurally similar GSK656 (Fig. 1) was not active against *M. avium*. The disparity in anti-NTM potency of these two benzoxaboroles could reflect differences in their ability to bind to different mycobacterial LeuRS homologs. Indeed, a recent report that GSK656 is inactive against *M. avium* suggested that this compound’s activity against *M. abscessus* may be due to the greater sequence similarity between the LeuRS homologs of *M. abscessus* and *M. tuberculosis* (44). Interestingly, the differences between the LeuRS editing domains of *M. avium* versus *M. tuberculosis* and *M. abscessus* do not occur in the active site, but in neighboring amino acid residues that may alter or restrict access to the benzoxaborole-tRNA<sub>Leu</sub> adduct binding pocket (Fig. S1) (44). The higher potency of GSK656 against *M. abscessus* compared to *M. avium* was also unusual since dual *M. tuberculosis-M. abscessus* hits are more likely to be *M. avium* hits.
than vice-versa (19). Our observation that two closely related members of the same drug class can have differential anti-NTM potency shows that an empirical approach is still required to identify a broadly active NTM compound from a drug class with reported TB activity. It also suggests that TB drug development programs should incorporate testing for anti-NTM potency early in the flowchart if the aim is to achieve broad anti-mycobacterial activity.

EC/11770 was active across the *M. abscessus* complex, which remains the most difficult NTM infection to treat, with no reliable cure (15). EC/11770 was also potent across the *M. avium* complex, which is the most commonly isolated NTM lung pathogen (9). Within the *M. avium* complex, EC/11770 was active against *M. chimaera*, an emerging NTM pathogen associated with cardiac surgery (45). Thus, EC/11770 is well-positioned to treat a range of clinically relevant NTM infections. Combined with the fact that EC/11770 was active against *M. tuberculosis*, this NTM active compound also has the potential to be a pan-antimycobacterial agent.

As observed previously and in this study (41), macrolides used in NTM treatment lose potency against *M. abscessus* growing as a biofilm *in vitro*. The inability of current NTM drugs to effectively target bacterial biofilms is thought to contribute to poor clinical outcomes in the treatment of NTM infections (43). In this context, EC/11770’s ability to retain its activity against *M. abscessus* biofilms is significant and its inclusion in NTM drug regimens could improve efficacy.
As EC/11770 demonstrated *in vivo* efficacy in the *M. abscessus* mouse infection model, this compound can now be considered for further development as a treatment for NTM infections. Notably, the low (10 mg/kg) dose of EC/11770 was sufficient to achieve a CFU reduction on par with a 250 mg/kg dose of clarithromycin – a common macrolide used for NTM infections. Thus, EC/11770 may provide an alternative to macrolide-based NTM treatment regimens, which face both intrinsic and acquired resistance in NTM (11, 46, 47). Rapid emergence of drug resistance has been reported for another benzoxaborole tested as a treatment for urinary tract infections (48). While studies on clinical mycobacterial resistance to benzoxaboroles are lacking, the frequency of resistance for EC/11770 in *M. abscessus* is 100-fold lower than that observed for other benzoxaboroles in *M. tuberculosis* (29). Combined with the fact that NTM treatment involves multi-drug chemotherapy (8, 9), we expect the risk of developing benzoxaborole resistance in NTM to be greatly reduced.

In conclusion, we screened advanced TB actives for NTM activity and identified EC/11770 as a broad-spectrum anti-NTM compound, introducing a new drug class (benzoxaboroles) and drug target (LeuRS) for NTM drug discovery. Broad microbiological profiling, pharmacokinetic and efficacy data establish EC/11770 as a promising preclinical candidate for NTM. This study also provides proof-of-concept that *de novo* NTM drug discovery starting with TB actives is an efficient approach, offering new hope for treating this class of bacterial infections.

**MATERIALS AND METHODS**

**Bacterial strains, culture media and drugs.**
M. abscessus Bamboo was isolated from the sputum of a patient with amyotrophic lateral sclerosis and bronchiectasis and was provided by Wei Chang Huang, Taichung Veterans General Hospital, Taichung, Taiwan. M. abscessus Bamboo whole-genome sequencing showed that the strain belongs to M. abscessus subsp. abscessus and harbors an inactive clarithromycin-sensitive \textit{erm}(41) C28 sequevar (32, 49). M. avium 11 was isolated from the bone marrow of a patient with acquired immunodeficiency syndrome with disseminated infection and was provided by Jung-Yien Chien and Po-Ren Hsueh, National Taiwan University Hospital, Taipei. Whole genome sequencing showed that the strain belongs to M. avium subsp. hominissuis (33).

\textit{Mycobacterium} abscessus subsp. abscessus ATCC 19977, harboring the inducible clarithromycin resistance-conferring \textit{erm}(41) T28 sequevar (50), was purchased from the American Type Culture Collection (ATCC). \textit{Mycobacterium} abscessus subsp. bolletii CCUG 50184T, harboring the inducible clarithromycin resistance-conferring \textit{erm}(41) T28 sequevar (51), and \textit{Mycobacterium} abscessus subsp. massiliense CCUG 48898T, harboring the nonfunctional \textit{erm}(41) deletion sequevar (52) were purchased from the Culture Collection University of Goteborg (CCUG). \textit{M. tuberculosis} H37Rv ATCC 27294 and \textit{M. intracellulare} ATCC 13950 were purchased from the ATCC, and \textit{M. chimaera} CCUG 50989T was purchased from the CCUG.

Clinical isolates covering the \textit{M. abscessus} complex (M9, M199, M337, M404, M422, M232, M506, M111) were provided by Jeanette W. P. Teo (Department of Laboratory Medicine, National University Hospital, Singapore). The subspecies and \textit{erm}(41) sequevars of these isolates were determined previously (38). M. abscessus subsp. abscessus K21 was isolated from
a patient and provided by Sung Jae Shin (Department of Microbiology, Yonsei University College of Medicine, Seoul, South Korea) and Won-Jung Koh (Division of Pulmonary and Critical Care Medicine, Samsung Medical Center, Seoul, South Korea). This strain harbors the inactive, clarithromycin-sensitive \textit{erm}(41) C28 sequevar as determined previously (39).

For general bacteria culturing and certain MIC experiments, Middlebrook 7H9 broth (BD Difco) supplemented with 0.5% albumin, 0.2% glucose, 0.085% sodium chloride, 0.0003% catalase, 0.2% glycerol, and 0.05% Tween 80. Unless otherwise stated, solid cultures were grown on Middlebrook 7H10 agar (BD Difco) supplemented with 0.5% albumin, 0.2% glucose, 0.085% sodium chloride, 0.5% glycerol, 0.0003% catalase, and 0.006% oleic acid. Cation-adjusted Mueller-Hinton (CAMH) broth was prepared by first preparing Mueller-Hinton broth (Oxoid CM0405) according to manufacturer instructions and then supplementing aseptically with sterile solutions of CaCl$_2$ and MgSO$_4$ to achieve CLSI recommended divalent cation levels (Ca$^{2+}$, 25 mg/L; Mg$^{2+}$, 12.5 mg/L).

EC/11770 and GSK656 were provided by GlaxoSmithKline. The synthesis of EC/11770 is described in patent WO 2015021396 (Example 10, page 70). Clarithromycin was purchased from Sigma-Aldrich (C9742). All drugs were prepared as 10 mM stocks in 100% DMSO.

**MIC Assay in 96-well Plate Format.**

Unless otherwise stated, MIC Determination was carried out in 96-well plate format as previously described (19, 38). 96-well plates were initially set up with 100 µl of 7H9 per well. For each compound, a ten-point two-fold dilution series starting at twice the desired highest
concentration was dispensed onto the 96-well plates using a Tecan D300e Digital Dispenser,

with the DMSO concentration normalized to 2%. A bacteria culture grown to mid-log phase

(OD$_{600}$ = 0.4-0.6) was diluted to OD$_{600}$ = 0.1 (1 x 10$^7$ CFU/ml). 100 µl of the resulting bacteria

suspension was dispensed onto the 96-well plates containing compounds to give a final volume

of 200 µl per well with an initial OD$_{600}$ = 0.05 (5 x 10$^6$ CFU/ml) and final DMSO concentration

of 1%. Final compound concentration ranges were typically 50-0.098 µM or 6.25-0.012 µM, but

were adjusted to 100-0.195 µM for testing of EC/11770-resistant mutant strains. Untreated

control wells were included on each plate that contain bacteria suspension and 1% DMSO. Plates

were sealed with parafilm, stored in boxes with wet paper towels and incubated at 37°C with

shaking (110 rpm). Plates were incubated for 3 days (M. abscessus complex), 4 days (M. avium

complex) or 7 days (M. tuberculosis). To determine growth, OD$_{600}$ was measured using a Tecan

Infinite M200 plate reader on Day 0 and Day 3, 4 or 7. Two biological replicates were

performed. Clarithromycin (M. abscessus and M. avium complexes) or Rifampicin (M.
tuberculosis) were included in each experiment as a positive control.

For each well on the 96-well plate, bacterial growth was calculated by subtracting the Day 0

OD$_{600}$ value from the endpoint (Day 3, 4 or 7) OD$_{600}$ value. For each compound series, the

bacterial growth values for the untreated control wells was averaged to give the average drug-

free bacterial growth. For compound-containing wells, percentage growth was calculated by

dividing their growth values by the average drug-free bacterial growth for the compound series

and multiplying by 100. For each compound series, we plotted percentage growth vs compound

concentration. By visual inspection of the dose-response curve, we determined the MIC of a

compound as the compound concentrations that would result in 90% growth inhibition.
For MIC Determination in CAMH broth, experiments were set up as described above with the following changes. Compounds were dispensed onto 96-well plates with 100 µl of CAMH broth per well. A mid-log phase bacteria culture (initially in 7H9) was washed once and resuspended with CAMH broth. The culture was then diluted to $\text{OD}_{600} = 0.1$ (1 x $10^7$ CFU/ml) using CAMH broth before dispensing to the 96-well plates.

**MIC and MBC Determination in Culture Tubes.**

*M. abscessus* Bamboo culture was grown to mid-log phase ($\text{OD}_{600} = 0.4$-$0.6$) and diluted to $\text{OD}_{600} = 0.1$ (1 x $10^7$ CFU/ml). 1.2 ml aliquots of the resulting bacteria suspension were transferred into 14 ml vented, round-bottom tubes (Thermo Fisher 150268, Rochester, NY, United States). A ten-point two-fold dilution series of the compound was prepared, starting at 100 times the desired highest concentration. The compound concentration range tested was 100-0.195 µM. For each drug concentration tested, 12 µl of drug stock was added to two tubes and vortexed. 12 µl of DMSO was added to two tubes as the untreated controls (1% final DMSO concentration). From each tube, 200 µl was transferred to wells on a 96-well plate and the $\text{OD}_{600}$ was measured using a Tecan Infinite M200 plate reader (Day 0 reading). The tubes (1 ml final volume) were incubated on a tilted rack at 37°C on an orbital shaker at 220 rpm. On Day 2, tubes were vortexed before transferring 200 µl onto a 96-well plate to measure the $\text{OD}_{600}$ again (Day 2 reading). To determine the MIC, Day 0 and Day 2 $\text{OD}_{600}$ values were analyzed as previously described for MIC determination in 96-well plate format. To determine the MBC, CFU measurement was done for the $\text{OD}_{600} = 0.1$ bacteria suspension on Day 0 and for each tube on Day 2. Specifically, serial 10-fold dilutions were prepared in phosphate buffered saline (Thermo...
Fisher 10010023) containing 0.025% Tween-80 (PBS/Tween-80) and plated on 7H10 agar. The MBC was defined as the lowest concentration of drug that reduced the CFU/ml value by 10-fold relative to the Day 0 CFU/ml.

Biofilm Growth Inhibition Assay.

The biofilm growth inhibition assay was performed as previously described (41). Innovotech MBEC 96-well Biofilm Assay Plates (Innovotech 19111, Edmonton, AB, United States) were used, and the supplier’s manual was followed with minor modifications. Mid-log phase *M. abscessus* Bamboo precultures (OD$_{600}$ = 0.4-0.6) were spun down at 3200 × g for 10 min at 25°C and washed with 7H9 medium without Tween-80 (7H9nt). Bacteria were resuspended into 25 ml 7H9nt to an OD$_{600}$ = 0.0125 (1.0 × 10$^6$ CFU/ml). 150 µl of bacteria suspension was dispensed into each well of MBEC multi-titer plates and the polystyrene protrusions (pegs) of the MBEC lid were inserted into the culture-containing wells for 24 h at 37°C on an orbital shaker at 110 rpm to allow attachment of the bacteria to the pegs and initiation of biofilm growth. The lids with the pegs were transferred to a new MBEC multi-titer plate containing 150 µl of fresh 7H9nt medium per well without bacteria (0 h time point). After that, the pegs with growing biofilm were transferred once a day to a new multi-titer plate containing fresh 7H9nt medium. To measure growth of the biofilm formed on the peg, the pegs were washed in 200 µl of 7H9nt medium before they were aseptically removed and placed in 1.7 ml microcentrifuge tubes (VWR 87003-294, Rador, PA, United States) containing 500 µl PBS/Tween-80. The microcentrifuge tubes were vigorously vortexed at 2,000 rpm for 90 s at 25°C to detach the bacteria from the pegs before samples were serially diluted and plated for the determination of CFU/peg. To determine the biofilm MIC of antibiotics, appropriate drug concentrations or DMSO (untreated
control, 1% final concentration) were added at the 24 h timepoint and CFU were determined after 48 h of incubation with antibiotic (72 h time point). The average drug-free biofilm growth was calculated by subtracting the average 24 h CFU/peg value from the average 72 h CFU/peg value for the untreated control pegs. The biofilm MIC was defined as the lowest drug concentration that reduced the CFU/peg by 90% relative to the average drug-free biofilm growth. The biofilm MBC was defined as the concentration of drug that reduced the CFU/peg by 10-fold relative to the CFU/peg at 24 h.

Selection of Spontaneous Resistant Mutants.

Spontaneous resistant mutants were selected as described previously (53). Exponentially growing M. abscessus Bamboo culture (10^7 to 10^9 CFU) was plated on 7H10 agar containing 100 μM EC/11770. The plates were incubated for 7 days at 37°C. Apparent resistant colonies were purified and confirmed by re-streaking on agar containing the same concentration of drug. Two independent batches of resistant mutants were generated in this manner. Genomic DNA was extracted as described previously using the phenol-chloroform method (54). Sanger sequencing of the leuS (MAB_4923) genomic region was performed by Genewiz (GENEWIZ, Inc., South Plainfield, NJ, USA; www.genewiz.com) using four primers (leuS-UpStrm-Fwd, 5’ GTCCCGAAGTTAATAACCGC 3’; leuS-Int-Fwd, 5’ GACGCAGTGGATTTTCCTAC 3’; leuS-Int-Rev, 5’ AGGCTCTTTCCGATCTTCCC 3’; leuS-DwnStrm-Rev, 5’ AGAACTCACCAGACATGAAG 3’). Based on the domain map of LeuRS in M. tuberculosis (29), we identified the editing domain of M. abscessus LeuRS as amino acid residues V292 to K502 (nucleotides 874 to 1506) and determined that all spontaneous resistant mutants possessed a missense mutation in this region.
Kinetic aqueous solubility assay.

The aqueous solubility of test compounds were measured using an in-house method utilizing quantification via chemiluminescent nitrogen detection (CLND): 5 μl of 10 mM DMSO stock solution was diluted to 100 μl with pH 7.4 phosphate buffered saline and equilibrated for 1 h at RT, filtered through Millipore Multiscreen HTS-PCF filter plates (MSSL BPC). The eluent is quantified by a suitably calibrated flow injection CLND (or CAD). This assay has a dynamic range between the lower detection limit of 1 and 500 μM, governed by the protocol’s 1:20 dilution into pH 7.4 phosphate buffer solution from nominal 10 mM DMSO stock.

ChromlogD assay.

The Chromatographic Hydrophobicity Index (CHI) values are measured using reversed phase HPLC column (50 x 2 mm 3 μM Gemini NX C18, Phenomenex, UK) with fast acetonitrile gradient at starting mobile phase of pHs 2, 7.4 and 10.5. CHI values are derived directly from the gradient retention times by using a calibration line obtained for standard compounds. The CHI value approximates to the volume % organic concentration when the compound elutes. CHI is linearly transformed into ChromlogD by least-square fitting of experimental CHI values to calculated ClogP values for over 20K research compounds using the following formula:

\[ \text{ChromlogD} = 0.0857 \times \text{CHI} - 2.00 \]

The average error of the assay is ±3 CHI unit or ±0.25 ChromlogD.

AMP (Artificial Membrane Permeability) assay.
A 8% L-a-phosphatidylcholine (EPC) in 1% cholesterol decane solution and a 1.8% EPC in cholesterol decane solution were prepared. The lipid solution was then aliquoted into 4 ml capped vials, sealed with parafilm and stored in -20°C freezer. The lipid solution was then transferred from 4 ml vial into a 96-well half area plate (130 μl/well) for daily assay usage. An additional 50 mM phosphate buffer with 0.5% encapsin, pH at 7.4 was prepared. The assay was run by the Biomek FX and Biomek software. The assay procedure is written under the Biomek software. For one batch assay, it can test two 96-well sample plates with at least one standard on each sample plate. The total assay time was about 4 hours. 3.5 μl of lipid solution were added to the filler plate, shaken for 12 seconds, and 250 μl of buffer were added to donor side and 100 μl to the receiver side. The assay plate was shaken for 45 min before adding the compounds. The test compounds (2.5 μl) were added to the donor side. The assay was run as replicates: Assay plates 1 and 2 tested the sample plate 1; assay plates 3 and 4 tested the sample plate 2. The assay plates were then incubated and shaken for 3 hours at room temperature. The assay samples were transferred to the HPLC analysis plates and 100 μl of receiver solution were aspirated and transferred to the receiver for analysis. Similarly, another 100 μl from the donor solution were transferred to the donor analysis plate. Compound concentration was measured by HPLC at different time-points.

**Stability in microsomes.**

Intrinsic clearance (CLi) values were determined in mouse and human liver microsomes. Test compounds (final concentration 0.5 μM) were incubated at 37 °C for 30 min in 50 mM potassium phosphate buffer (pH 7.4) containing 0.5 mg microsomal protein/ml. The reaction was started by addition of cofactor NADPH. At 0, 5 and 20 min, an aliquot (90 μl) was taken,
quenched with acetonitrile-methanol containing an appropriate internal standard, centrifuged and analyzed by LC-MS/MS. The intrinsic clearance (CL\(_i\)) was determined using the following equation:

\[
\text{CL}_i = k \times (\text{ml of incubation/mg microsomal protein}) \times (\text{mg microsomal protein/g liver})
\]

Where \(k\) is the turn-over rate constant of the ln (% remaining compound) vs time regression and mg microsomal protein/g liver is 52.5 for both mouse and human.

**Pharmacokinetics studies.**

For pharmacokinetic studies, CD-1 male mice (22-25 g) were used for intravenous route and C57BL/6 female mice (18-20 g) were used for oral route. All animal studies were ethically reviewed and carried out in accordance with European Directive 2010/63/EU and the GSK Policy on the Care, Welfare and Treatment of Animals.

EC/11770 was administered by intravenous route at 1 mg/kg single dose in saline and by oral gavage at 1 mg/kg and 10 mg/kg single doses in 1% methyl cellulose (1% MC). Aliquots of 20 \(\mu\)l of blood were taken from the lateral tail vein by puncture from each mouse (\(n = 3\) per route and dose) at 5, 15 and 30 minutes, 1, 2, 4, 6, 8 and 24 hours post-dose for intravenous route and at 15, 30, and 45 minutes, 1, 2, 4, 6, 8 and 24 hours post-dose for oral route. The blood aliquots were mixed with 40 \(\mu\)l of water and stored at -80°C prior to analysis. The samples were processed by protein precipitation: aliquots of 20 \(\mu\)l were mixed with acetonitrile/methanol (80:20 v/v) and then filtered in 0.45 \(\mu\)m well-plates (hydrophobic PTFE-Millipore). The filtrates were analysed by UPLC-MS/MS for the establishment of compound concentration. The UPLC-MS/MS system included an UPLC Acquity (Waters) and an API4000 mass spec. (AB Sciex). A
volume of 7.5 μl of sample were injected into the system, with an UPLC solvent gradient of 2 min and with a positive MRM mass detection mode.

Pharmacokinetic analysis was performed by non-compartmental data analysis (NCA) with Phoenix WinNonlin 6.3 (Pharsight, Certara L.P) and supplementary analysis was performed with GraphPad Prism 6 (GraphPad Software, Inc).

**M. abscessus Mouse Infection Model.**

*In vivo* efficacy determinations were carried out as described previously, using 8-week-old female NOD.CB17-Prkdc<sup>scid</sup>/NCrCrl (NOD SCID) mice (Charles River Laboratories) and the *M. abscessus* subsp. *abscessus* K21 strain (39). Briefly, anesthetized animals were infected by intranasal delivery of ~10<sup>6</sup> CFU of *M. abscessus* subsp. *abscessus* K21. Acute infection was achieved within one day. Drugs or the vehicle control was administered to NOD SCID mice once daily for 10 consecutive days by oral gavage, starting from 1 day post-infection. Clarithromycin was formulated in 0.4% methyl cellulose–sterile water and administered at a dose of 250 mg/kg. EC/11770 was formulated in 0.4% methyl cellulose–sterile water and administered at 10 mg/kg. All mice were euthanized 24 h after the last dose (11 days post-infection), and their lungs and spleen were aseptically removed prior to homogenization. The bacterial load in these organs was determined by plating serial dilutions of the organ homogenates onto Middlebrook 7H11 agar (BD Difco) supplemented with 0.2% (vol/vol) glycerol and 10% (vol/vol) OADC. The agar plates were incubated for 5 days at 37°C prior to counting of colonies. All studies were conducted in accordance with the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals and were reviewed the Institutional Animal Care and Use Committee either at GSK or by the ethical review process at the institution where the work was performed. All experiments were conducted in accordance with the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals and were reviewed the Institutional Animal Care and Use Committee either at GSK or by the ethical review process at the institution where the work was performed.
involving live animals were approved by the Institutional Animal Care and Use Committee of the Center for Discovery and Innovation, Hackensack Meridian Health.

**Sequence analysis of mycobacterial LeuRS editing domains.**

Amino acid sequences of LeuRS from *M. tuberculosis* H37Rv ATCC 27294, *M. abscessus* Bamboo, and *M. avium* 11 were aligned using Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo). The alignment was formatted using ESPript 3.0 (http://espript.ibcp.fr/) (55).

**ACKNOWLEDGMENTS**

We are grateful to Wei Chang Huang (Taichung Veterans General Hospital, Taichung, Taiwan) for providing *M. abscessus* Bamboo, to Jeanette W.P. Teo (Department of Laboratory Medicine, National University Hospital, Singapore) for providing the collection of *M. abscessus* clinical isolates, and to Sung Jae Shin (Department of Microbiology, Yonsei University College of Medicine, Seoul, South Korea) and Won-Jung Koh (Division of Pulmonary and Critical Care Medicine, Samsung Medical Center, Seoul, South Korea) for providing *M. abscessus* K21. Research reported in this work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI132374 and by the Cystic Fibrosis Foundation under Award Number DICK17XX00 to TD.

**REFERENCES**

1. Tortoli E. 2019. The Taxonomy of the Genus Mycobacterium, p 1-10. In Velayati AA, Farnia P (ed), Nontuberculous Mycobacteria (NTM) doi:10.1016/b978-0-12-814692-7.00001-2. Academic Press.
2. Vinnard C, Longworth S, Mezochow A, Patrawalla A, Kreiswirth BN, Hamilton K. 2016. Deaths Related to Nontuberculous Mycobacterial Infections in the United States, 1999-2014. Ann Am Thorac Soc 13:1951-1955.

3. Johansen MD, Herrmann JL, Kremer L. 2020. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol 18:392-407.

4. To K, Cao R, Yegiazaryan A, Owens J, Venketaraman V. 2020. General Overview of Nontuberculous Mycobacteria Opportunistic Pathogens: Mycobacterium avium and Mycobacterium abscessus. J Clin Med 9:2541.

5. Philalay JS, Palermo CO, Hauge KA, Rustad TR, Cangelosi GA. 2004. Genes required for intrinsic multidrug resistance in Mycobacterium avium. Antimicrob Agents Chemother 48:3412-8.

6. Machado D, Cannalire R, Santos Costa S, Manfroni G, Taburrini O, Cecchetti V, Couto I, Viveiros M, Sabatini S. 2015. Boosting Effect of 2-Phenylquinoline Efflux Inhibitors in Combination with Macrolides against Mycobacterium smegmatis and Mycobacterium avium. ACS Infect Dis 1:593-603.

7. Luthra S, Rominski A, Sander P. 2018. The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Mycobacterium abscessus Drug Resistance. Front Microbiol 9:2179.

8. Strnad L, Winthrop KL. 2018. Treatment of Mycobacterium abscessus Complex. Semin Respir Crit Care Med 39:362-376.

9. Griffith DE. 2018. Treatment of Mycobacterium avium Complex (MAC). Semin Respir Crit Care Med 39:351-361.
10. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, Bottger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. 2020. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline: Executive Summary. Clin Infect Dis doi:10.1093/cid/ciaa241.

11. Nash KA, Brown-Elliott BA, Wallace RJ, Jr. 2009. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 53:1367-76.

12. Tamaoki J, Takeyama K, Tagaya E, Konno K. 1995. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 39:1688-90.

13. Spagnolo P, Fabbri LM, Bush A. 2013. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 42:239-51.

14. Kwak N, Park J, Kim E, Lee CH, Han SK, Yim JJ. 2017. Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis. Clin Infect Dis 65:1077-1084.

15. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. 2011. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 52:565-71.

16. Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuernberger EL, Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M,
Sassetti CM, Sizemore CF, Winthrop KL, Zelazny AM. 2019. Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. Am J Respir Crit Care Med 199:947-951.

17. Wu ML, Aziz DB, Dartois V, Dick T. 2018. NTM drug discovery: status, gaps and the way forward. Drug Discov Today 23:1502-1519.

18.Anonymous. ClinicalTrials.gov, on U.S. National Library of Medicine. https://clinicaltrials.gov. Accessed September 1, 2020.

19. Low JL, Wu ML, Aziz DB, Laleu B, Dick T. 2017. Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates. Front Microbiol 8:1539.

20. Sarathy JP, Ganapathy US, Zimmerman MD, Dartois V, Gengenbacher M, Dick T. 2020. TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. Antimicrob Agents Chemother 64:e02404-19.

21. Pang YL, Poruri K, Martinis SA. 2014. tRNA synthetase: tRNA aminoacylation and beyond. Wiley Interdiscip Rev RNA 5:461-80.

22. Nagel GM, Doolittle RF. 1991. Evolution and relatedness in two aminoacyl-tRNA synthetase families. Proc Natl Acad Sci U S A 88:8121-5.

23. Hughes J, Mellochs G. 1978. Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid. Biochem J 176:305-18.

24. Hughes J, Mellochs G. 1980. Interaction of pseudomonic acid A with Escherichia coli B isoleucyl-tRNA synthetase. Biochem J 191:209-19.

25. Sassanfar M, Kranz JE, Gallant P, Schimmel P, Shiba K. 1996. A eubacterial Mycobacterium tuberculosis tRNA synthetase is eukaryote-like and resistant to a eubacterial-specific antisynthetase drug. Biochemistry 35:9995-10003.
26. Baker SJ, Zhang YK, Akama T, Lau A, Zhou H, Hernandez V, Mao W, Alley MR, Sanders V, Plattner JJ. 2006. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem 49:4447-50.

27. Rock FL, Mao W, Yaremchuk A, Tukalo M, Crepin T, Zhou H, Zhang YK, Hernandez V, Akama T, Baker SJ, Plattner JJ, Martinis SA, Benkovic SJ, Cusack S, Alley MR. 2007. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 316:1759-61.

28. Mascarenhas AP, An S, Rosen AE, Martinis SA, Musier-Forsyth K. 2009. Fidelity Mechanisms of the Aminoacyl-tRNA Synthetases, p 155-203. In Köhrer C, RajBhandary UL (ed), Protein Engineering doi:10.1007/978-3-540-70941-1_6. Springer Berlin Heidelberg, Berlin, Heidelberg.

29. Palencia A, Li X, Bu W, Choi W, Ding CZ, Easom EE, Feng L, Hernandez V, Houston P, Liu L, Meewan M, Mohan M, Rock FL, Sexton H, Zhang S, Zhou Y, Wan B, Wang Y, Franzblau SG, Woolhiser L, Gruppo V, Lengaerts AJ, O'Malley T, Parish T, Cooper CB, Waters MG, Ma Z, Ioeerger TR, Sacchettini JC, Rullas J, Angulo-Barturen I, Perez-Herran E, Mendoza A, Barros D, Cusack S, Plattner JJ, Alley MR. 2016. Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase. Antimicrob Agents Chemother 60:6271-80.

30. Li X, Hernandez V, Rock FL, Choi W, Mak YSL, Mohan M, Mao W, Zhou Y, Easom EE, Plattner JJ, Zou W, Perez-Herran E, Giordano I, Mendoza-Losana A, Alemparte C, Rullas J, Angulo-Barturen I, Crouch S, Ortega F, Barros D, Alley MRK. 2017. Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-
(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J Med Chem 60:8011-8026.

31. Tenero D, Derimanov G, Carlton A, Tonkyn J, Davies M, Cozens S, Gresham S, Gaudion A, Puri A, Muladiatan M, Rullas-Trincado J, Mendoza-Losana A, Skingsley A, Barros-Aguirre D. 2019. First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment. Antimicrob Agents Chemother 63:e00240-19.

32. Yee M, Klinzing D, Wei JR, Gengenbacher M, Rubin EJ, Dick T. 2017. Draft Genome Sequence of Mycobacterium abscessus Bamboo. Genome Announc 5:e00388-17.

33. Yee M, Klinzing D, Wei JR, Gengenbacher M, Rubin EJ, Chien JY, Hsueh PR, Dick T. 2017. Draft Genome Sequence of Mycobacterium avium 11. Genome Announc 5:e00766-17.

34. Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J, Jiricek J, Keller TH, Chatterjee A, Tan MP, Ujjini M, Rao SP, Camacho L, Bifani P, Mak PA, Ma I, Barnes SW, Chen Z, Plouffe D, Thayalan P, Ng SH, Au M, Lee BH, Tan BH, Ravindran S, Nanjundappa M, Lin X, Goh A, Lakshminarayana SB, Shoen C, Cynamon M, Kreiswirth B, Dartois V, Peters EC, Glynne R, Brenner S, Dick T. 2010. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun 1:57.

35. Mukherjee D, Wu ML, Teo JWP, Dick T. 2017. Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro. Antimicrob Agents Chemother 61:e01298-17.
36. Woods GL, Brown-Elliott BA, Conville PS, Desmond EP, Hall GS, Lin G, Pfyffer GE, Ridderhof JC, Siddiqi SH, Wallace RJ, Jr., Warren NG, Witebsky FG. 2011. In 2nd (ed), Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes, Wayne (PA).

37. Lee MR, Sheng WH, Hung CC, Yu CJ, Lee LN, Hsueh PR. 2015. Mycobacterium abscessus Complex Infections in Humans. Emerg Infect Dis 21:1638-46.

38. Aziz DB, Low JL, Wu ML, Gengenbacher M, Teo JWP, Dartois V, Dick T. 2017. Rifabutin Is Active against Mycobacterium abscessus Complex. Antimicrob Agents Chemother 61:e00155-17.

39. Dick T, Shin SJ, Koh WJ, Dartois V, Gengenbacher M. 2020. Rifabutin Is Active against Mycobacterium abscessus in Mice. Antimicrob Agents Chemother 64:e01943-19.

40. van Ingen J, Turenne CY, Tortoli E, Wallace RJ, Jr., Brown-Elliott BA. 2018. A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review. Int J Syst Evol Microbiol 68:3666-3677.

41. Yam YK, Alvarez N, Go ML, Dick T. 2020. Extreme Drug Tolerance of Mycobacterium abscessus "Persisters". Front Microbiol 11:359.

42. Qvist T, Eickhardt S, Kragh KN, Andersen CB, Iversen M, Hoiby N, Bjarndahl T. 2015. Chronic pulmonary disease with Mycobacterium abscessus complex is a biofilm infection. Eur Respir J 46:1823-6.

43. Fennelly KP, Ojano-Dirain C, Yang Q, Liu L, Lu L, Progulske-Fox A, Wang GP, Antonelli P, Schultz G. 2016. Biofilm Formation by Mycobacterium abscessus in a Lung Cavity. Am J Respir Crit Care Med 193:692-3.
44. Dong W, Li S, Wen S, Jing W, Shi J, Ma Y, Huo F, Gao F, Pang Y, Lu J. 2020. In Vitro Susceptibility Testing of GSK656 against Mycobacterium Species. Antimicrob Agents Chemother 64:e01577-19.

45. van Ingen J, Kohl TA, Kranzer K, Hasse B, Keller PM, Katarzyna Szafranska A, Hillemann D, Chand M, Schreiber PW, Sommerstein R, Berger C, Genoni M, Ruegg C, Troillet N, Widmer AF, Becker SL, Herrmann M, Eckmanns T, Haller S, Holler C, Debast SB, Wolfhagen MJ, Hopman J, Kluymans J, Langelaar M, Notermans DW, Ten Oever J, van den Barselaar P, Vonk ABA, Vos MC, Ahmed N, Brown T, Crook D, Lamagni T, Phin N, Smith EG, Zambon M, Serr A, Gotting T, Ebner W, Thurmer A, Utpatel C, Sproer C, Bunk B, Nubel U, Bloemberg GV, Bottger EC, Niemann S, Wagner D, Sax H. 2017. Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study. Lancet Infect Dis 17:1033-1041.

46. Wallace RJ, Jr., Meier A, Brown BA, Zhang Y, Sander P, Onyi GO, Bottger EC. 1996. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 40:1676-81.

47. Meier A, Heifets L, Wallace RJ, Jr., Zhang Y, Brown BA, Sander P, Bottger EC. 1996. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis 174:354-60.

48. O'Dwyer K, Spivak AT, Ingraham K, Min S, Holmes DJ, Jakielaszek C, Rittenhouse S, Kwan AL, Livi GP, Sathe G, Thomas E, Van Horn S, Miller LA, Twynholm M, Tomayko J, Dalessandro M, Caltabiano M, Scangarella-Oman NE, Brown JR. 2015. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during
treatment of complicated urinary tract infections. Antimicrob Agents Chemother 59:289-98.

49. Bastian S, Veziris N, Roux AL, Brossier F, Gaillard JL, Jarlier V, Cambau E. 2011. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 55:775-81.

50. Ripoll F, Pasek S, Schenowitz C, Dossat C, Barbe V, Rottman M, Macheras E, Heym B, Herrmann JL, Daffe M, Brosch R, Risler JL, Gaillard JL. 2009. Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 4:e5660.

51. Choi GE, Cho YJ, Koh WJ, Chun J, Cho SN, Shin SJ. 2012. Draft genome sequence of Mycobacterium abscessus subsp. bolletii BD(T). J Bacteriol 194:2756-7.

52. Cho YJ, Yi H, Chun J, Cho SN, Daley CL, Koh WJ, Shin SJ. 2013. The genome sequence of 'Mycobacterium massiliense' strain CIP 108297 suggests the independent taxonomic status of the Mycobacterium abscessus complex at the subspecies level. PLoS One 8:e81560.

53. Yang T, Moreira W, Nyantakyi SA, Chen H, Aziz DB, Go ML, Dick T. 2017. Amphiphilic Indole Derivatives as Antimycobacterial Agents: Structure-Activity Relationships and Membrane Targeting Properties. J Med Chem 60:2745-2763.

54. Negatu DA, Yamada Y, Xi Y, Go ML, Zimmerman M, Ganapathy U, Dartois V, Gengenbacher M, Dick T. 2019. Gut Microbiota Metabolite Indole Propionic Acid Targets Tryptophan Biosynthesis in Mycobacterium tuberculosis. mBio 10:e02781-18.
Robert X, Gouet P. 2014. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res 42:W320-4.

**TABLES**

**Table 1.** Activities of EC/11770 and GSK656 against *M. tuberculosis*, *M. abscessus*, and *M. avium*.

| Strain                      | Medium | CLR | EC/11770 | GSK656 |
|-----------------------------|--------|-----|----------|--------|
| *M. tuberculosis* H37Rv ATCC 27294 | 7H9    | ND  | 0.56     | 0.08   |
| *M. abscessus* Bamboo       | 7H9    | 0.23| 1.2      | 0.27   |
| *M. abscessus* Bamboo       | CAMH   | 0.07| 0.7      | ND     |
| *M. avium* 11               | 7H9    | 0.30| 4.0      | >50    |

*MIC values are the mean of two independent experiments.

*CLR, clarithromycin; ND, not determined.

MIC of rifampicin against *M. tuberculosis* H37Rv was 0.66 µM.

MIC value of GSK656 against *M. tuberculosis* H37Rv is from published literature (30).

**Table 2.** Broad spectrum antimycobacterial profiling of EC/11770.

| Strain                      | Strain Type                          | CLR | EC/11770 |
|-----------------------------|--------------------------------------|-----|----------|
| *M. abscessus* Bamboo       | Clinical Isolate, Screening Strain    | 0.23| 1.2      |
| *M. abscessus* subsp. abscessus ATCC 19977 | Culture Collection Reference Strain  | 0.90| 0.70     |
| *M. abscessus* subsp. massiliense CCUG 48898T | Culture Collection Reference Strain  | 0.19| 0.71     |
| *M. abscessus* subsp. bolletii CCUG 50184T | Culture Collection Reference Strain  | 2.5 | 1.3      |
| *M. abscessus* subsp. abscessus M9   | Clinical Isolate                     | 0.73| 0.49     |
| *M. abscessus* subsp. abscessus M199  | Clinical Isolate                     | 2.7 | 0.93     |
| *M. abscessus* subsp. abscessus M337  | Clinical Isolate                     | 0.90| 0.50     |
| *M. abscessus* subsp. abscessus M404  | Clinical Isolate                     | 0.20| 0.52     |
| *M. abscessus* subsp. abscessus M422  | Clinical Isolate                     | 0.65| 0.33     |
| *M. abscessus* subsp. bolletii M232   | Clinical Isolate                     | 0.95| 0.67     |
| *M. abscessus* subsp. bolletii M506   | Clinical Isolate                     | 0.28| 0.48     |
M. abscessus subsp. massiliense M111 Clinical Isolate 0.24 0.95
M. abscessus subsp. abscessus K21 Clinical Isolate, Infection Model 0.40 0.60
M. avium 11 Clinical Isolate, Screening Strain 0.30 4.0
M. intracellularare ATCC 13950 Culture Collection Reference Strain 0.15 0.37
M. chimaera CCUG 50989T Culture Collection Reference Strain 0.19 1.7

Table 3. Growth inhibitory and bactericidal activity of EC/11770 against planktonic and biofilm

M. abscessus

|          | MIC (µM) | MBC (µM) |
|----------|----------|----------|
|          | CLR EC/11770 | CLR EC/11770 |
| Planktonic | 0.28 3.0 | >100 >100 |
| Biofilm    | 1.6 3.1  | >100 50   |

"MIC and MBC values are the mean of two independent experiments.

CLR, clarithromycin.

Table 4. Characterization of M. abscessus EC/11770-resistant mutants

| Strain         | Batch | MIC (µM) | LeuS Mutations |
|----------------|-------|----------|----------------|
| M. abscessus Bamboo | -     | 0.31 0.9 | None           |
| RM1            | 1     | 0.36 >100| LeuS A428P     |
| RM2            | 1     | 0.38 >100| LeuS K502E     |
| RM3            | 1     | 0.43 62  | LeuS V417M     |
| RM4            | 2     | 0.42 >100| LeuS T327R     |
| RM5            | 2     | 0.46 75  | LeuS V417M     |

"MIC values are the mean of two independent experiments.

CLR, clarithromycin.

Table 5. Physicochemical and pharmacokinetic properties of EC/11770

| CLND Solubility (µM) | 349 |

"MIC values are the mean of two independent experiments.

CLR, clarithromycin.
Mouse and Human Hepatic Microsomes Stability (*in vitro*)

|                          | Mouse *in vitro* CL\text{int} (ml/min/g tissue) | Human *in vitro* CL\text{int} (ml/min/g tissue) |
|--------------------------|-------------------------------------------------|-----------------------------------------------|
| Mouse                    | <0.5                                            | <0.5                                          |

Mouse pharmacokinetic parameters (*in vivo*)

|                          | Mouse                                        | Human                                       |
|--------------------------|----------------------------------------------|---------------------------------------------|
| In vivo CL (ml/min/kg)    | 5.0 (0.1)                                    | 0.5 (0.1)                                   |
| V\text{ss} (L/kg)         | 2.4 (0.1)                                    | 0.75-2.0                                    |
| t\text{1/2} (h)           | 5.3 (0.3)                                    | 0.75-2.0                                    |
| AUC\text{int} (ng*h/ml)   | 3338 (79)                                    | 3556 (179)                                  |

Oral administration-1 mg/kg & 10 mg/kg

|                          | 1 mg/kg                                      | 10 mg/kg                                    |
|--------------------------|----------------------------------------------|---------------------------------------------|
| C\text{max,1} mg/kg (ng/ml) | 341 (51)                                    | 4,393 (1,260)                               |
| C\text{max,10} mg/kg (ng/ml)| 4,393 (1,260)                                | 4,053 (908)                                 |
| T\text{max,1} mg/kg (h)     | 1.0-2.0                                      | 1.0-2.0                                     |
| T\text{max,10} mg/kg (h)    | 0.75-2.0                                     | 0.75-2.0                                    |
| AUC\text{0-24h,1} mg/kg (ng*h/ml) | 3556 (179)                               | 4053 (908)                                  |
| AUC\text{0-24h,10} mg/kg (ng*h/ml) | 4053 (908)                                | 4053 (908)                                  |
| DNAUC\text{0-24h,1} mg/kg (ng*h/ml per mg/kg) | 3556 (179)                      | 4053 (908)                                  |
| DNAUC\text{0-24h,10} mg/kg (ng*h/ml per mg/kg) | 4053 (908)                      | 4053 (908)                                  |
| %F\text{1} mg/kg           | ~100                                         | ~100                                         |
| %F\text{10} mg/kg          | ~100                                         | ~100                                         |

*CLND solubility, aqueous solubility via Chemiluminescent Nitrogen Detection; AMP, Artificial Membrane Permeability; CL\text{int}, intrinsic clearance; *in vivo* CL, *in vivo* clearance; V\text{ss}, volume of distribution at Steady State; t\text{1/2}, half-life; AUC\text{int}, area under the concentration-time curve extrapolated to infinite; C\text{max}, highest concentration of drug in the blood; T\text{max}, time taken to reach C\text{max}; AUC\text{0-24h}, area under the concentration-time curve from time 0-24h; DNAUC, dose normalized area under the concentration-time curve; %F, bioavailability.

average (SD). T\text{max} is expressed as a range of values. %F is expressed as a percentage.

FIGURE LEGENDS

Figure 1. Structures of EC/11770 and GSK656.

Figure 2. Blood Concentration Versus Time Profiles for EC/11770. Whole blood concentrations vs time profiles of EC/11770 after intravenous (IV) administration of 1 mg/kg and oral (PO)
administration of 1 and 10 mg/kg. MIC values of *M. abscessus* Bamboo and K21 planktonic cultures (Table 2) and *M. abscessus* Bamboo biofilms (Table 3) are plotted.

**Figure 3.** EC/11770 is active against *M. abscessus* in vivo. Lung CFU (A) and Spleen CFU (B) from NOD SCID mice one day after intranasal infection with *Mab* (Drug free Day 1) and following daily oral administration of drug free vehicle, clarithromycin (CLR) or EC/11770 for ten days (Day 11). Data represent the mean plus standard deviation of six mice per treatment group. Statistical significance of the results was analyzed by one-way analysis of variance (ANOVA) multi-comparison and Tukey’s posttest (*P < 0.05; **P < 0.01; ***P < 0.001).
